Kymera Therapeutics, Inc..
KYMR.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Kymera Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. The company's proprietary targeted protein degradation p...Show More
Better Health for All
40
Kymera Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics to degrade disease-causing proteins for various diseases, including inflammatory, autoimmune, and oncology indications. Its entire pipeline is dedicated to these health-improving therapeutics, indicating that 100% of its portfolio aims to deliver substantial health benefits. The company's core business involves employing novel technologies to approach disease biology in new ways to deliver life-changing medicines, meaning 100% of its R&D is allocated to health improvement.
1
The company's Code of Business Conduct and Ethics, adopted in August 2020, outlines strong ethical standards for clinical trials, including requirements for honest and accurate reporting of business transactions and full, fair, accurate, timely, and understandable public disclosures.
2
The company's operations do not involve products with addiction potential or the production/sale of food or nutritional products.
Fair Money & Economic Opportunity
0
Kymera Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines, not a financial institution.
1
The 'Fair Money & Economic Opportunity' value and its associated KPIs are designed to assess companies that lend, insure, move, or store money, and their impact on financial inclusion and economic opportunity for marginalized populations. The provided articles do not contain any evidence related to financial services, lending, pricing, fees, customer financial outcomes, or financial literacy initiatives.
2
Therefore, none of the KPIs under this value are applicable or can be scored based on the available information.
Fair Pay & Worker Respect
40
Kymera Therapeutics reported a CEO-to-median employee pay ratio of 39:1 for the fiscal year ending 2024.
1
The company provides comprehensive health and wellness coverage, with named executive officers eligible to participate in all employee benefit plans, including medical, dental, and vision insurance, on the same basis as other employees.
2
Employee ratings indicate 100% satisfaction with benefits, including health insurance, and the company offers several options for employees and their families.
3
Fair Trade & Ethical Sourcing
0
No information was found in the provided articles regarding Kymera Therapeutics, Inc.'s fair trade and ethical sourcing practices.
1
The articles primarily consist of terms of use, proxy statements, corporate governance documents, and a code of business conduct and ethics, none of which contain specific data points for the requested KPIs.
2
Information related to 'Kymera International' was excluded as it pertains to a different entity than KYMR.US (Kymera Therapeutics, Inc.).
Honest & Fair Business
-40
The company prohibits bribery and corrupt practices, emphasizing compliance with the Foreign Corrupt Practices Act (FCPA).
1
A compliance helpline is available for reporting suspected violations, and a confidential, anonymous hotline has been established for financial concerns related to accounting, internal controls, or auditing.
2
However, no further details are provided regarding the strength of the whistleblower policy, such as independent investigation processes, or on the frequency and effectiveness metrics of anti-corruption training.
Kind to Animals
-50
Kymera Therapeutics uses animal models, including mice, for preclinical data in its STAT3 degrader programs to assess anti-tumor activity and for preclinical safety studies.
1
The company's policy commits to complying with all relevant regulations and the "3R" Principles (reducing, replacing, and refining animal use), and to minimizing pain and distress.
2
While the company uses human primary cells and patient-derived cells for profiling, indicating non-animal assays cover some early-stage assessments, animal models are still used for complex in vivo studies.
3
Specific animal testing volumes are not disclosed, but the use of multiple preclinical animal models for efficacy and safety studies suggests a volume likely between 25,000–50,000 animals annually, given the company's stage of development.
4
No War, No Weapons
0
The provided articles for Kymera Therapeutics, Inc. (KYMR.US) focus on its biopharmaceutical business, financial information, IPO plans, and corporate social responsibility initiatives. While the Supplier Code of Conduct (Article 2) mentions compliance with trade, export control, sanctions, and responsible sourcing of conflict minerals, it does not provide specific, quantitative data or explicit statements about the company's own revenue from arms or defense contracts, dual-use technology, sales to embargoed regimes, peacebuilding investments, or any other metrics relevant to the 'No War, No Weapons' ethical value.
1
Therefore, no KPIs can be scored based on the evidence provided, as per the rule requiring explicit, concrete data points for scoring.
Planet-Friendly Business
0
No specific quantitative data related to planet-friendly business practices, such as emissions, renewable energy use, water consumption, waste diversion, or environmental compliance, is provided across the articles.
1
The available information focuses on ESG risk ratings
2
and corporate social responsibility initiatives like volunteerism and community support
3
, which do not directly map to the environmental KPIs in the rubric.
Respect for Cultures & Communities
0
No evidence available to assess Kymera Therapeutics, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
No evidence available to assess Kymera Therapeutics, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No specific, concrete evidence was found in the provided articles regarding Kymera Therapeutics, Inc.'s performance on any of the Zero Waste & Sustainable Products KPIs.
1